Literature DB >> 9892685

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

R Aharoni1, D Teitelbaum, R Arnon, M Sela.   

Abstract

The synthetic random amino acid copolymer Copolymer 1 (Cop 1, Copaxone, glatiramer acetate) suppresses experimental autoimmune encephalomyelitis, slows the progression of disability, and reduces relapse rate in multiple sclerosis (MS). Cop 1 binds to various class II major histocompatibility complex (MHC) molecules and inhibits the T cell responses to several myelin antigens. In this study we attempted to find out whether, in addition to MHC blocking, Cop 1, which is immunologically cross-reactive with myelin basic protein (MBP), inhibits the response to this autoantigen by T cell receptor (TCR) antagonism. Two experimental systems, "prepulse assay" and "split APC assay," were used to discriminate between competition for MHC molecules and TCR antagonism. The results in both systems using T cell lines/clones from mouse and human origin indicated that Cop 1 is a TCR antagonist of the 82-100 epitope of MBP. In contrast to the broad specificity of the MHC blocking induced by Cop 1, its TCR antagonistic activity was restricted to the 82-100 determinant of MBP and could not be demonstrated for proteolipid protein peptide or even for other MBP epitopes. Yet, it was shown for all the MBP 82-100-specific T cell lines/clones tested that were derived from mice as well as from an MS patient. The ability of Cop 1 to act as altered peptide and induce TCR antagonistic effect on the MBP p82-100 immunodominant determinant response elucidates further the mechanism of Cop 1 therapeutic activity in experimental autoimmune encephalomyelitis and MS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892685      PMCID: PMC15188          DOI: 10.1073/pnas.96.2.634

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Basic encephalitogenic protein: A simplified purification on sulphoethyl-sephadex.

Authors:  H Hirshfeld; D Teitelbaum; R Arnon; M Sela
Journal:  FEBS Lett       Date:  1970-05-01       Impact factor: 4.124

2.  Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad.

Authors:  D F Hunt; H Michel; T A Dickinson; J Shabanowitz; A L Cox; K Sakaguchi; E Appella; H M Grey; A Sette
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

3.  Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAs molecules.

Authors:  A G Lamont; A Sette; R Fujinami; S M Colón; C Miles; H M Grey
Journal:  J Immunol       Date:  1990-09-15       Impact factor: 5.422

Review 4.  Molecular events mediating T cell activation.

Authors:  A Altman; K M Coggeshall; T Mustelin
Journal:  Adv Immunol       Date:  1990       Impact factor: 3.543

Review 5.  Antigen recognition and peptide-mediated immunotherapy in autoimmune disease.

Authors:  D E Smilek; C B Lock; H O McDevitt
Journal:  Immunol Rev       Date:  1990-12       Impact factor: 12.988

6.  Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1.

Authors:  D Teitelbaum; R Aharoni; M Sela; R Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

7.  Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex.

Authors:  R Aharoni; D Teitelbaum; R Arnon; J Puri
Journal:  Nature       Date:  1991-05-09       Impact factor: 49.962

8.  Characterization of the immune response to a secondary encephalitogenic epitope of basic protein in Lewis rats. II. Biased T cell receptor V beta expression predominates in spinal cord infiltrating T cells.

Authors:  D P Gold; M Vainiene; B Celnik; S Wiley; C Gibbs; G A Hashim; A A Vandenbark; H Offner
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

9.  High affinity for class II molecules as a necessary but not sufficient characteristic of encephalitogenic determinants.

Authors:  M Wall; S Southwood; J Sidney; C Oseroff; M F del Guericio; A G Lamont; S M Colón; T Arrhenius; F C Gaeta; A Sette
Journal:  Int Immunol       Date:  1992-07       Impact factor: 4.823

10.  Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

Authors:  D Teitelbaum; R Milo; R Arnon; M Sela
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

View more
  38 in total

Review 1.  Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

Authors:  R Hohlfeld
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

Review 2.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 3.  Antigen specific immunotherapy of multiple sclerosis.

Authors:  L Steinman; P Conlon
Journal:  J Clin Immunol       Date:  2001-03       Impact factor: 8.317

Review 4.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

5.  The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.

Authors:  N N Spirin; D S Kasatkin
Journal:  Neurosci Behav Physiol       Date:  2009-01

6.  Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Aaron Boster; Mary Pat Bartoszek; Colleen O'Connell; David Pitt; Michael Racke
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

7.  Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms.

Authors:  Joel N H Stern; Zsolt Illés; Jayagopala Reddy; Derin B Keskin; Eric Sheu; Masha Fridkis-Hareli; Hiroyuki Nishimura; Celia F Brosnan; Laura Santambrogio; Vijay K Kuchroo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

8.  Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells.

Authors:  Zsolt Illés; Joel N H Stern; Jayagopala Reddy; Hanspeter Waldner; Marcin P Mycko; Celia F Brosnan; Stephan Ellmerich; Daniel M Altmann; Laura Santambrogio; Jack L Strominger; Vijay K Kuchroo
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

Review 9.  Neurogenesis and neuroprotection in the CNS--fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders.

Authors:  Ruth Arnon; Rina Aharoni
Journal:  Mol Neurobiol       Date:  2007-10-11       Impact factor: 5.590

Review 10.  Dendritic cells as therapeutic targets in neuroinflammation.

Authors:  Felix Luessi; Frauke Zipp; Esther Witsch
Journal:  Cell Mol Life Sci       Date:  2016-03-12       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.